Human induced pluripotent stem cells (hiPSCs) are of great interest for biomedical applications because of their unlimited self-renewal and potential to differentiate into any adult cell type. However, the production of hiPSCs in high quantities that are sufficient for cell-based therapies and cell-loaded implants through planar adherent culture is not feasible and suffers from a lack of scalability. To overcome some of these limitations, a promising approach is to culture hiPSCs in suspension. Here, we describe our 14-day suspension culturebased protocol to generate clinically-relevant quantities of hiPSCs as cell-only aggregates. The approach described here may also contribute to hiPSC banking efforts.
